目的：评价DC-CIK细胞治疗晚期转移性鼻咽癌患者的疗效。方法：回顾性分析2011年8月至2015年6月解放军第八一医院肿瘤生物治疗科行DC-CIK细胞治疗的29例晚期转移性鼻咽癌患者。观察DC-CIK细胞治疗前后患者的疗效、安全性及EB病毒VCA-IgA抗体水平和淋巴细胞亚群的变化。结果：29例鼻咽癌患者经DC-CIK细胞治疗后客观缓解率为0，疾病控制率为65.5%，中位生存时间为42个月，1~4年生存率都为68.0%，无严重不良反应。治疗后29例患者的外周血EB病毒VCA-IgA抗体显著低于治疗前\[（30.88±3.91）U/ml vs (49.86±5.02) U/ml, P<0.05）\]。经细胞治疗后CD8+ T细胞显著上升（P<0.05）、CD4+/ CD8+ T细胞比值显著下降（P<0.05）。结论：DC-CIK细胞治疗转移性鼻咽癌安全、可行，能产生一定的临床获益。

Objective:To evaluate the curative efficacy of DC-CIK cells on the patients with advanced metastatic nasopharyngeal carcinoma. Methods: Twenty nine patients with advanced metastatic nasopharyngeal carcinoma treated with DC-CIK cells in Department of Tumor Biotherapy, the 81st Hospital of PLA during August 2011 to June 2015 were retrospectively analyzed. Changes of EB virus VCA-IgA antibody level and lymphocyte subsets before and after DC-CIK cells treatment, as well as its curative efficacy and safety were observed. Results: After the treatment with DC-CIK cells, the objective remission rate of the 29 patients was 0, disease control rate of the patients was 65.5%, media survival time of the patients was 42 months, and the 1-4 years survival rates were 68.0% for all. All the patients had no serious adverse reactions. EB virus VCA-IgA antibody in peripheral blood of the patients after the treatment was significantly lower than that before the treatment (\[30.88±3.91\] U/ml vs \[49.86±5.02\] U/ml, P<005). After the treatment with DC-CIK cells, CD8+ T cells numbers were obviously increased (P<0.05) with the ratio of CD4+/CD8+T significantly decreased (P<0.05). Conclusion: DC-CIK cells immunotherapy for the patients with advanced metastatic nasopharyngeal carcinoma might be safe and feasible, and could produce some clinical efficacy.

南京军区医学科技创新资助项目（No.14MS052）